Marketresearchnews

Thursday, 25 October 2018

Discover Market Study on Conjugate Vaccine Market - Pipeline Review, 2018

Synopsis of the Global Conjugate vaccines Market
Market Scenario
Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached to the strong protein antigen. The major drivers for the growth of the global conjugate vaccine market are initiatives taken by the government, advancement in the vaccine formulation, and prevention of major infectious diseases, for instance meningitis and others. Furthermore, increasing investments by the companies in research & development, rising focus on immunization programs, and growing demand for vaccination expected to boost the growth of the market over the review period. Increasing prevalence of infectious diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market during the forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4387

The strength or effectiveness of conjugate vaccines needs to improve, which may hamper the growth of the market.
The global conjugate vaccine market is expected to grow at a healthy CAGR of 10.5% during the forecast period 2017-2023.
FIGURE 1 Global Conjugate Vaccines Market, by Indication, 2016 (%)

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Intended Audience

Research and development (R&D) companies
Government and independent research laboratories
Government and independent regulatory authorities
Academic medical institutes and universities
Pharmaceutical industries

Segments
The global Conjugate vaccine is segmented on the basis of type, indication, and end users. On the basis type it is segmented into Haemophilus B, monovalent, multivalent, others. On the basis of indication, it is segmented into Influenza, Pneumococcal, Meningococcal, others. On the basis of end users, it is segmented into pediatrics and adults.
Research Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Regional Analysis of the Global Conjugate vaccines Market
On the regional basis, the market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the largest market due to a significant use of the vaccine for preventing diseases and favorable conditions for research and development.
Europe is the second largest Conjugate Vaccines market in the globe followed by Asia Pacific. In Europe availability of funds for research and development activities and growing emphasis on research for prevention measures of diseases is increasing. Whereas, Asia Pacific shows the fastest growth in this market due to the increasing prevalence of communicable diseases. Developing countries in this region are emphasizing research on diseases caused to children’s and preventive measures for treating them. Mainly, India and China are expected to be an emerging and the fastest growing market due to the increasing population and prevalence of diseases.
The Middle East & Africa owns the lowest market in the global conjugate vaccines market due to less availability medical facilities.
Key Players in the Global Conjugate vaccines Market
Some of the key players in this market are GlaxoSmithKline plc. Merck & Co., Inc. (U.S), Fablife. (India), SutroVax Inc.(U.S), Sanofi Pasteur SA.(France), Pfizer (U.S), Sinovac Biotech Ltd. (China), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(U.S).
Browse More Details @ https://www.marketresearchfuture.com/reports/conjugate-vaccine-market-4387
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Palliative Care Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario

Global Palliative Care market is expected to grow during the forecast period (2018–2023) at a CAGR ~8.1 %.

Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6336

However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.

Segmentation

The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.

Regional Market Summary

The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.

In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the Global Palliative Care market are Vitas Healthcare Corporation, Skilled Healthcare Group Incorporated, Sunrise Senior Living LLC, Kindred Healthcare Incorporated, Gentiva Health Services Incorporated, Home Instead Senior Care Incorporated, Amedisys Incorporated, Genesis HealthCare Corporation.

Browse More Details @ https://www.marketresearchfuture.com/reports/palliative-care-market-6336

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Market Overview of Cerebral Palsy Market Clinical Trials Review, 2018

Market Scenario

The global cerebral palsy market is expected to grow significantly over the forecast period. Cerebral palsy (CP) refers to a group of neurological conditions that affect muscle movement and coordination. CP can be caused by damage that occurs to the immature developing brain of an infant. In addition to this, other possible causes of CP include asphyxia neonatorum, bleeding into the brain, brain infections, and severe jaundice in the infants. Cerebral palsy is the most common form of childhood disability. According to the Cerebral Palsy Guidance, around 10,000 babies are born each year in the US with cerebral palsy.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6334

The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.

Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.

Segmentation

The global cerebral palsy market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.

The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.

The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cerebral palsy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European cerebral palsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The cerebral palsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebral palsy market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global cerebral palsy market.

Regional Market Summary

Global Cerebral Palsy Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global cerebral palsy market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.

Europe is expected to hold the second largest position in the global cerebral palsy market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.

The cerebral palsy market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse More Details @ https://www.marketresearchfuture.com/reports/cerebral-palsy-market-6334

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Antihistamine Drugs Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Synopsis of the Global Antihistamine drugs Market
Market Scenario
Antihistamines are drugs mainly used for treating allergies. They are also used to treat motion sickness, insomnia and anxiety. They work by acting against a chemical called histamine which leads to many allergic symptoms. Antihistamines may cause side effects such as dizziness, dry mouth, nervousness, irritability, blurry vision and decreased appetite.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4266

The global antihistamine drugs market is expected to grow at a CAGR of 9.8% during the forecast period and is estimated to reach USD 280 million by 2023.

Key Players in the Global Antihistamine drugs Market

Some of the key players in this market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)

Segments

The global antihistamine drugs market is segmented on the basis of types which includes sedating and non-sedating antihistamines. Sedating antihistamines are further sub-segmented into brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, carbinoxamine and others. Non-sedating antihistamines are further sub-segmented into fexofenadine, loratadine, loratadine odt, and others.

On the basis of route of administration, the market is segmented into oral route, parenteral route and rectal route. Parenteral route segmented is further sub-segmented into intramuscular, subcutaneous and intravenous route.

On the basis of indication, the market is segmented into allergy, urticaria, dermatitis, and others. And on the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies and others.

Regional Analysis of the Global Antihistamine drugs Market

The American region accounts for the largest share of the global market due to rising prevalence of allergy rhinitis and rising demand for diagnosis and treatment of allergic disease. According to the American College of Allergy Asthma and Immunology, allergic asthma, food allergy, and eczema are the most common types of allergies found in the U.S.

Europe is the second largest market that holds a noticeable share of the global antihistamine drugs market. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 50% of all Europeans will suffer from allergy in coming years.

In Asia Pacific, increase in the demand for drugs for the treatment of allergies and skin diseases drive the market growth. There has been a rise in the number of dermatology clinics across Asia Pacific from past few years. High rates of allergic rhinitis and increasing awareness regarding treatments available for allergy is poised to drive the growth of this market in Asia Pacific.

The Middle East & Africa, the market shows steady but positive growth due to the rising prevalence of nasal allergies.

Browse More Details @ https://www.marketresearchfuture.com/reports/antihistamine-drugs-market-4266

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wednesday, 24 October 2018

Mucormycosis Market, Trends, Absolute Opportunity and Value Chain 2018

Market Scenario

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5440

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.
Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.
The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.
Research Methodology:

Sources: Annual reports, Press release, White paper, and Company presentation

Intended Audience:

Mucormycosis Drug Suppliers
Mucormycosis Drug Manufacturers
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities

Segmentation:
The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.
On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Regional Analysis:
The global mucormycosis market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.
Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.

While the Middle East & Africa had the lowest share in antifungal treatment market, in 2016.

Key Players:

Some of key the players in the global mucormycosis market are Abbott Laboratories (U.S.), Biocon Limited (India), Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland), Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Digital Wound Measurement Devices Market Global Market by Treatments, Causes, Drugs and Diet 2018-2023

Market Scenario

The global digital wound measurement devices market is expected to witness a positive growth during the forecast period. Digital wound measurement devices enable monitoring of chronic wounds and deliver the appropriate drug dose to speed up the process of healing. Chronic wounds if not treated on time can lead to severe infections and amputations. Hence, digital wound measurement devices allow delivering tailored treatments after the 2D or 3D assessment of the infection and inflammation. The increasing number of patients suffering from chronic wounds drives the market growth. According to the Intermountain Healthcare (2017), 6.5 million people in the US suffer from chronic wounds. Diabetic wounds are severe, and the process of healing is very long and eventually may lead to amputations. Hence factors such as growing diabetic patients, rising geriatric population, and an increasing number of surgeries are major factors influencing the growth of the market. The emergence of smartphones, rapid use of advanced digital tools, and the advent of telehealth for wound care will also contribute for the market to grow.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6289

However, factors such as, the inability of the device to provide additional information about wounds such as moistness or exudation and high costs of digital devices are expected to restrict the market growth during the forecast period.

Segmentation

The global digital wound measurement devices market is segmented on the basis of wound type, product, and end-user. The digital wound measurement devices market, by wound type is sub-segmented into a diabetic ulcer, chronic wounds, burns, incisional, and traumatic. The product segment is sub-segmented into contact wound measuring devices and non-contact wound measuring devices.

On the basis of end-user, the market is segmented into hospitals, clinics, and ambulatory surgical centers.

On the basis of region, the global digital wound measurement devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players for the global digital wound measurement devices market are WoundRight Technologies Tissue Analytics, Parable Health, ARANZ Medical Limited, eKare, Inc, KCI, an Acelity Company, WoundMatrix, Inc., WoundZoom Inc., Kent Imaging Inc., WoundRight Technologies, LLC, WoundVision, LLC, Hitachi Healthcare Americas, and Smith & Nephew plc.

Regional Market Summary

The digital wound measurement devices market is dominated by North America owing to the rising prevalence of chronic wounds and technological advancements in the healthcare sector. In June 2018, KCI, an Acelity Company announced the launch of Nurse2Nurse (N2N) Mobile App for wound care nurses. The app allows interactions with clinicians and shares credible insights and information for better patient care.

It is estimated that Europe was the second largest in the global digital wound measurement devices market. The increasing technological advancement and research for wound care along with government support in Europe drive the market growth in this region. The European Wound Management Association will conduct its 29th conference by June 2019 in Gothenburg, Sweden in the presence of several international wound management communities with the common goal of improving the care of wound patients.

Asia-Pacific was projected to be the fastest growing region for the global digital wound measurement devices market. Key factors such as rising geriatric population, growing diabetic patient pool, high incidence chronic wounds, and developing healthcare infrastructure drive the market in this region. According to the Asian Diabetes Prevention Initiative, 60% of the world diabetic population is in Asia. This provides favorable backgrounds for the market to grow in Asia.

The Middle East and Africa holds the least share of the global digital wound measurement devices market due to the presence of stringent government policies and poor economic growth. However, growing awareness and increasing investments by private market players in this region can boost the market growth.

Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/digital-wound-measurement-devices-market-6289

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Breast Biopsy Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario

The global breast biopsy market is expected to grow significantly during the forecast period (2018–2023).

A biopsy is a small operation performed to remove tissues from an area of concern in the body. Breast biopsy is a procedure that involves testing of small samples of breast tissues for detecting breast cancer. Breast biopsies are conducted using minimal invasive biopsy systems, owing to minimal disfigurement and pain.

There are different types of biopsy procedures depending on the technique, such as core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB) recommended by the doctor based on the location, size, and other characteristics of the breast abnormality.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6288

The increase in the prevalence of breast cancer, especially among women above the age of 35 during menopause (are more susceptible to breast cancer) and growth in the awareness regarding breast cancer screening programs drive the market growth. However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restraints for the market include the high cost of surgical procedures and risks involved in them. Conversely, the emergence of technologically-advanced and minimally invasive breast biopsy devices are expected to provide lucrative opportunities in the untapped market.

Segmentation

The global breast biopsy market has been segmented on the basis of product, technique type, guidance technology, and end-user.

On the basis of product, the market has been classified as biopsy needles, biopsy tables, biopsy wires, guidance systems, and others.
On the basis of technique type, the market is classified into fine needle aspiration biopsy, core needle biopsy, biopsy markers, MRI-guided core needle biopsy, surgical biopsy, wire localization, and sentinel node biopsy. Further, core needle biopsy is divided into stereotactic core needle biopsy, vacuum-assisted biopsy, ultrasound-guided core biopsy, and freehand core-needle biopsy. Surgical biopsy is segmented into incisional biopsy and excisional biopsy.

On the basis of guidance technology, the market is classified into ultrasound-guided, mammography-guided magnetic resonance, CT-guided biopsy, and other image-guided breast biopsy (PET and thermography).

On the basis of end-user, the market is divided into hospitals, ambulatory surgical centers, diagnostic centers, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European breast biopsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The breast biopsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The breast biopsy market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the breast biopsy market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies and continuous development by companies operating in cancer diagnostics. The global breast biopsy market is largely focused on North America and Europe, which is valued to account for more than 50% of the market share.

The European market is expected to hold the second largest market share as breast cancer is most common in the UK and Belgium. According to the Cancer Research UK in 2015, 55122 new cases of invasive breast cancer were diagnosed.
The market share in the Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities, growing demand for advanced technology, better adoption rate, increasing government initiatives, and rising healthcare expenditure.

The market in the Middle East and Africa is expected to account for the smallest share of the global breast biopsy market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global breast biopsy market are Leica Biosystems, C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Becton, Dickinson and Company, Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Johnson & Johnson, Galini SRL, Intact Medical Corporation, Conceptus INC, Hologic Inc., Karl Storz GmbH & Co. Kg, GE Healthcare.

Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/breast-biopsy-market-6288

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com